Multi-Targeted Therapies in Non-Small Cell Lung Cancer

Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signaling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interfering at different stages to avoid cancer cell resistance to therapy. For this reason, new strategies for the simultaneous inhibition of multiple molecular targets are being pursued.

Whole process control and precision therapy in lung cancer

Lung cancer is one of the most common malignant tumors in the world. Non-small cell lung cancer （NSCLC） accounts for approximately 80% of lung cancer cases, and approximately 75% of patients are diagnosed in the middle and late stages. The treatment methods mainly include surgery, chemotherapy, radiotherapy, molecular targeted therapy, traditional Chinese medicine therapy, and immune therapy. We summarize the current status of lung cancer-related treatment options and targets.

Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer

One of the most important pathways in non-small cell lung cancer(NSCLC) is the epidermal growth factor receptor(EGFR) pathway. This pathway affects several crucial processes in tumor development and progression,including tumor cell proliferation,apoptosis regulation,angiogenesis,and metastatic invasion.Targeting EGFR is currently being intensely explored.We are witnessing the development of a number of potential molecular-inhibiting treatments for application in clinical oncology.In the last decade,the tyrosine kinase(TK) domain of the EGFR was identified in NSCLC patients,and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib.Unfortunately,there were primary and/or secondary resistance to these treatments,as shown by clinical trials.Subsequent molecular biology studies provided some explanations for the drug resistance phenomenon.The molecular mechanisms of resistance need to be clarified.An in-depth understanding of these targeted-therapy resistance may help us explore new strategies for overcoming or reversing the resistance to these inhibitors for the future of NSCLC treatment.

Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer

As a targeted therapy, antiangiogenic treatment has been increasingly studied for advanced non-small cell lung cancer(NSCLC) and has proven effective for the treatment of advanced NSCLC. Bevacizumab, a monoclonal antibody targeting angiogenesis, is the only antiangiogenic agent approved for use in combination with first-line chemotherapy for non-squamous NSCLC. Small-molecule inhibitors targeting the tyrosine kinase receptor have also shown promise when combined with standard chemotherapeutic agents in patients with advanced NSCLC. However, unlike bevacizumab, not all other antiangiogenic agents show significant benefits when combined with chemotherapy. As for the failures of most other combinations, the combination schedule may be an important reason that has so far been overlooked in clinical trials. This article reviews the combination of angiogenic agents with chemotherapy in the treatment of NSCLC.

肺癌脑转移研究进展:文献计量学和网络分析

目的应用文献计量学方法,分析近10年肺癌脑转移研究进展及发展趋势。方法使用Web of science检索2010—2019年有关肺癌脑转移的文献。利用Citespace软件从文献来源、作者、机构和国家分析研究现状。从文献共被引用和关键词分析发展趋势。结果近10年有关肺癌脑转移的研究呈现上升趋势。Lung cancer是发文量最多的期刊,不同作者的发文量分布相对均匀,差异不大。中国和美国是发文量最多的两个国家,韩国的研究者在该领域的国际合作与交流较为广泛。研究的热点从机制逐渐向全脑放疗、靶向治疗转移,免疫治疗也开始逐渐显现。患者治疗后生活质量改善方面也受到关注。结论近10年有关肺癌脑转移的研究稳步前进,已经形成了以肺癌脑转移治疗为主要研究方向的趋势,但国际间的合作与交流仍需加强,以提高研究质量。